/

6996.HK

ANTENGENE-BClosed

2.97+0.04 +1.19%HKD

HKSE · as of Oct 14, 04:08 ET · 15m delay

Open

3.06

Prev close

2.94

Day range

2.913.06

52-week range

2.766.28

Volume

858.60K0.69×

Mkt cap

1.82B

P/E ttm

33.00

Fwd P/E

-2.50

EPS ttm

0.0900

Div yield

0.00%

Earnings

—

From 52w high

−52.71%

Price Chart

Yahoo Finance · delayed

6996.HKOct 14, 2026O 3.06H 3.06L 2.90C 2.97+0.04 (+1.19%)Vol 858.60K

SMA 503.66
SMA 2004.04

1Y change −46.10% since Oct 13, 2025 close529 bars loadedTimes in Asia/Hong_KongDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

6996.HK ANTENGENE-B · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −15.14%
1 month: −13.28%
3 months: −33.85%
6 months: −51.71%
Year to date: −22.05%
1 year: −46.20%

Valuation & ownership

Market cap: 1.82B
Enterprise value: 1.33B
P/E (ttm): 33.00
Forward P/E: -2.50
PEG ratio: —
Price / book: 1.75
Price / sales (ttm): 3.22
EV / EBITDA: 7.22
EPS (ttm): 0.0900
EPS (forward): -1.19
Beta (5y monthly): 0.33
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 612.88M
Float: 356.36M
Short % of float: —
Short ratio (days): —
Held by insiders: 37.10%
Held by institutions: 7.85%
Avg volume (3m): 1.24M
50-day average: 3.68
200-day average: 4.06
52-week change: −46.20%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 32.6
vs 50-day SMA: −18.85%
vs 200-day SMA: −26.45%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.65%
Realised vol (20d, ann.): 52.7%
From 52-week high: −52.71%
From 52-week low: +7.61%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

4.86

+63.60% implied

Low 4.86Median 4.86High 4.86

Recommendation trend

Now0 / 1 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →trailing twelve months

DES

About ANTENGENE-B

Yahoo Finance profile

Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor for the treatment of cervical cancer and other advanced solid tumors. It also develops other clinical stage assets, such as ATG-022, an antibody-drug conjugate which is in Phase II for the treatment of patients with advanced or metastatic gastric cancer; ATG-031, an anti-CD24 monoclonal antibody, which is in Phase I for the treatment of advanced solid tumors; ATG-037, an CD73 inhibitor that is in Phase I for the treatment of locally advanced or metastatic solid tumors; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is I Phase I trial for the treatment of advanced/metastatic solid tumors and B-cell non Hodgkin lymphoma (B-NHL). In addition, the company's pre-clinical stage assets consist of ATG-042, an PRMT5-MTA inhibitor; ATG-201 a CD19 x CD3 T cell engager; ATG-102, a LILRB4 x CD3 T cell engager; ATG-106, a CDH6 x CD3 T cell engager; ATG-107, a FLT3 x CD3 T cell engager; and ATG-110, a LY6G6D x CD3 T cell engager. Further, the company develops AnTenGager, an 2+1 T cell engager platform which enables conditional T cell activation with reduced risk of cytokine release syndrome; and engages in the trading activities. Antengene Corporation Limited was founded in 2017 and is based in Shanghai, China.

Sector: Healthcare
Industry: Biotechnology
Employees: 122
Headquarters: Shanghai, China
Website: antengene.com

SEAS

Seasonality · 6996.HK

2020–2026 · monthly returns

Strongest month Feb +35.72%Weakest month Jun −11.13%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-12.1	-2.4	43.7	7.0	-11.5	-20.7	11.6	-6.7	-5.9	-14.2			−22.0%
2025	20.0	219.2	47.8	-18.5	39.3	-30.4	80.1	21.6	5.3	-22.8	-12.7	-15.7	+486.2%
2024	-35.5	-3.9	-19.4	2.0	-4.9	-19.6	-28.2	14.3	21.9	14.1	-24.7	-3.0	−67.5%
2023	0.2	-22.9	-26.9	-7.2	-31.5	-16.2	-0.6	-21.4	-0.8	29.2	32.9	-2.9	−61.2%
2022	-39.0	-2.5	13.7	-7.2	15.5	-1.3	-26.4	-19.8	-17.1	-3.5	18.6	30.4	−47.7%
2021	11.3	-11.4	-3.8	3.1	1.9	11.8	-25.3	-9.8	-19.5	-0.6	14.0	-16.2	−42.7%
2020												7.0	+7.0%

INSD

Insider Activity · 6996.HK

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Mar 23, 2026	Lung (Donald Andrew J.D.)Chief Financial Officer	Acquisition at price 0.53 per share.	235K	$124.17K
Mar 22, 2026	Lung (Donald Andrew J.D.)Chief Financial Officer	Acquisition at price 0.50 per share.	267.5K	$132.92K
Dec 30, 2025	Lung (Donald Andrew J.D.)Chief Financial Officer	—	83.5K	—
Dec 30, 2025	Mei (Jay M.D., Ph.D.)Chief Executive Officer	—	501K	—
Dec 30, 2025	Qian (Jing)Independent Non-Executive Director	—	8.3K	—
Dec 30, 2025	Tang (Sheng Cpa)Independent Non-Executive Director	—	8.3K	—
Dec 30, 2024	Lung (Donald Andrew J.D.)Chief Financial Officer	—	83K	—
Dec 30, 2024	Mei (Jay M.D., Ph.D.)Chief Executive Officer	—	498K	—
Dec 30, 2024	Qian (Jing)Independent Non-Executive Director	—	8.3K	—
Dec 30, 2024	Tang (Sheng Cpa)Independent Non-Executive Director	—	8.3K	—

6996.HK

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

6996.HK

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About ANTENGENE-B

Seasonality · 6996.HK

Insider Activity · 6996.HK

Congress Trades · 6996.HK

Investors Holding 6996.HK

Investors Holding 6996.HK

Congress Trades · 6996.HK

Insider Activity · 6996.HK

Seasonality · 6996.HK

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About ANTENGENE-B

Earnings & Dividends

News